What are the recommended treatment options for tics, including behavioral therapy and pharmacologic agents such as α2‑adrenergic agonists, antipsychotics, botulinum toxin, and tetrabenazine?

Treatment of Tics

For patients with tics requiring treatment, begin with behavioral therapy (habit reversal training/CBIT) as first-line, then escalate to α2-adrenergic agonists (clonidine or guanfacine) as initial pharmacotherapy, reserving antipsychotics (aripiprazole, risperidone) for moderate-to-severe cases, and considering botulinum toxin for focal tics or tetrabenazine for refractory cases.

When to Treat

Not all tics require treatment. Treatment is indicated only when tics cause functional impairment, social problems, pain, or significantly reduce quality of life 1, 2. Transient tic disorder affects 4-24% of elementary school children and is self-limited, lasting less than one year 3. Chronic tic disorders and Tourette syndrome warrant intervention when symptoms interfere with daily activities.

Treatment Algorithm

Step 1: Behavioral Therapy (First-Line)

• Comprehensive Behavioral Intervention for Tics (CBIT) or habit reversal training should be offered first for mild-to-moderate tics 1, 4
• This is particularly effective when patients can engage with the therapy and tics are not severely disabling
• No medication-related adverse effects, making this the safest initial approach

Step 2: α2-Adrenergic Agonists (Initial Pharmacotherapy)

When behavioral therapy is insufficient or unavailable:

• Clonidine or guanfacine are recommended as first-line pharmacologic agents 5, 1, 2, 6
• These agents have the most favorable side effect profile among medications
• Particularly useful when comorbid ADHD or sleep disturbances are present 7
• Guanfacine may additionally reduce tic severity, though evidence remains inconclusive 7
• Administer in the evening due to sedation/fatigue as common adverse effects 7

Step 3: Antipsychotics (Moderate-to-Severe Tics)

When α2-agonists fail or tics are moderate-to-severe:

Atypical antipsychotics are preferred over typical agents:

• Aripiprazole and risperidone have the strongest evidence for efficacy 1, 6
• Lower risk of extrapyramidal symptoms and tardive dyskinesia compared to typical antipsychotics 8

Typical antipsychotics (second-line):

• Pimozide and haloperidol are FDA-approved for Tourette syndrome 3
• Pimozide demonstrated superior efficacy and fewer side effects than haloperidol in controlled trials 3
• However, typical antipsychotics carry significant risk of extrapyramidal symptoms and tardive dyskinesia (up to 50% after 2 years in elderly) 8

Step 4: Specialized Interventions

Botulinum Toxin:

• Highly effective for focal motor and phonic tics, including coprolalia 9, 4
• Local injection approach minimizes systemic side effects
• Consider for patients with troublesome localized tics

Tetrabenazine (VMAT2 Inhibitor):

• Reserved for severe, refractory cases 1, 10, 6
• FDA-approved for chorea in Huntington's disease, used off-label for tics 11
• Black box warning: increases risk of depression and suicidality 11
• Contraindicated in patients with active suicidal ideation, untreated depression, hepatic impairment, or concurrent MAOI use 11
• Requires careful dose titration and monitoring

Deep Brain Stimulation:

• Reserved for "malignant" Tourette syndrome refractory to all medical therapies 12, 9, 4
• Requires multidisciplinary evaluation and age >20 years recommended 12

Critical Considerations for Comorbidities

ADHD with Tics:

• Stimulants do NOT worsen tics in most patients 5
• Multiple controlled studies show stimulants are highly effective for ADHD symptoms without increasing tic severity 5
• If tics remain problematic on stimulants, add α2-agonists (clonidine or guanfacine) 5
• Motor tics are no longer considered a contraindication to stimulant use 5

OCD with Tics:

• Treat with SSRIs or clomipramine for OCD symptoms 4, 13
• Atypical antipsychotics can address both tics and OCD 4

Substance Use Disorders:

• Non-stimulants (atomoxetine, α2-agonists) are first-line for comorbid ADHD due to abuse potential of stimulants 7

Common Pitfalls

• Do not use typical antipsychotics as first-line due to high risk of tardive dyskinesia and extrapyramidal symptoms
• Avoid benztropine or trihexyphenidyl for antipsychotic-induced extrapyramidal symptoms in this population 8
• Do not combine tetrabenazine with MAOIs, reserpine, deutetrabenazine, or valbenazine 11
• When using strong CYP2D6 inhibitors (fluoxetine, paroxetine) with medications metabolized by this pathway, reduce maximum doses accordingly 5
• Monitor for depression, suicidality, and behavioral changes with all pharmacologic treatments, especially tetrabenazine 11